tradingkey.logo
搜索

Glaukos Corp

GKOS
添加自选
144.420USD
0.0000.00%
收盘 06/26, 16:00美东报价延迟15分钟
8.43B总市值
亏损市盈率 TTM

关于 Glaukos Corp 公司

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Glaukos Corp简介

公司代码GKOS
公司名称Glaukos Corp
上市日期Jun 25, 2015
CEOBurns (Thomas William)
员工数量995
证券类型Ordinary Share
年结日Jun 25
公司地址1 Glaukos Way
城市ALISO VIEJO
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编92656
电话19493679600
网址https://www.glaukos.com
公司代码GKOS
上市日期Jun 25, 2015
CEOBurns (Thomas William)

Glaukos Corp公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
49.04K
-3.13%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
49.04K
-3.13%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%

常见问题

Glaukos Corp的前五大股东是谁?

Glaukos Corp 的前五大股东如下:Mr. Thomas William Burns

有多少机构持有Glaukos Corp(GKOS)的股份?

截至2026Q1,共有702家机构持有Glaukos Corp的股份,合计持有的股份价值约为59.35M,占公司总股份的101.04%。与2025Q4相比,机构持股有所增加,增幅为-2784097.00。

哪个业务部门对Glaukos Corp的收入贡献最大?

在2026Q1,Glaucoma业务部门对Glaukos Corp的收入贡献最大,创收421.07M,占总收入的82.98%。
KeyAI